Teachers Advisors LLC lifted its position in shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) by 21.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,329 shares of the biotechnology company’s stock after acquiring an additional 5,976 shares during the quarter. Teachers Advisors LLC owned approximately 0.11% of Edge Therapeutics worth $352,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Edge Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after acquiring an additional 19,973 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Edge Therapeutics by 1.1% during the 2nd quarter. Franklin Resources Inc. now owns 2,663,123 shares of the biotechnology company’s stock valued at $27,324,000 after acquiring an additional 30,100 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Edge Therapeutics by 1.7% during the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 200 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Edge Therapeutics during the 2nd quarter valued at $236,000. Finally, Rhumbline Advisers boosted its holdings in shares of Edge Therapeutics by 19.1% during the 2nd quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 3,195 shares in the last quarter. 49.22% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/11/16/teachers-advisors-llc-purchases-5976-shares-of-edge-therapeutics-inc-edge.html.

In related news, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $10.21, for a total transaction of $76,575.00. Following the completion of the transaction, the insider now directly owns 117,736 shares of the company’s stock, valued at approximately $1,202,084.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Albert N. Marchio II sold 2,500 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $10.42, for a total value of $26,050.00. Following the transaction, the insider now directly owns 3,361 shares of the company’s stock, valued at $35,021.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,500 shares of company stock valued at $409,465. 36.19% of the stock is owned by corporate insiders.

Several equities research analysts recently weighed in on the company. BidaskClub downgraded Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research raised Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Monday, November 6th.

Edge Therapeutics, Inc. (NASDAQ EDGE) opened at $9.23 on Thursday. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.20. Edge Therapeutics, Inc. has a 12-month low of $7.30 and a 12-month high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.11. research analysts anticipate that Edge Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.